Paper Details

  1. Home
  2. Paper Details

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.

Author: AcevesSeema, AkinladeBolanle, AminNikhil, BeazleyBethany, BredenoordAlbert J, ChehadeMirna, CollinsMargaret H, DellonEvan S, GiannelouAngeliki, HamiltonJennifer D, HiranoIkuo, KamalMohamed A, KosloskiMatthew P, LawsElizabeth, LimWei Keat, LucendoAlfredo J, MaloneyJennifer, MannentLeda P, McCannEilish, PatelKiran, PatelNaimish, RothenbergMarc E, RuddyMarcella, ShabbirArsalan, ShumelBrad, SpergelJonathan M, SunXian, WeinreichDavid R, WippermanMatthew F, YancopoulosGeorge D

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Subcutaneous dupilumab administered weekly to patients with eosinophilic esophagitis significantly improved histological outcomes and alleviated symptoms. Histologic remission occurred in 60% of patients receiving weekly dupilumab compared to 5% of those receiving placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. METHODS: We conducted a three-part, phase 3 trial in which patients 12 years of age or older underwent randomization in a 1:1 ratio to recei...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2205982

データ提供：米国国立医学図書館（NLM）

Dupilumab for Adults and Adolescents with Eosinophilic Esophagitis

This study explores the potential of dupilumab, a monoclonal antibody that blocks interleukin-4 and interleukin-13 signaling, as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory condition affecting the esophagus. The researchers conducted a three-part, phase 3 clinical trial to evaluate the efficacy and safety of dupilumab in patients 12 years of age or older with EoE. Their findings revealed that dupilumab, administered subcutaneously once weekly, significantly improved histologic outcomes and alleviated symptoms of EoE.

Dupilumab: A Promising Treatment for EoE

The study's results suggest that dupilumab could be a valuable treatment option for patients with EoE. It's a significant development, offering hope for improved management of this often challenging condition. The drug's ability to target specific immune pathways involved in EoE provides a targeted approach to treating the condition.

Managing EoE: A Collaborative Approach

EoE is a complex condition, and managing it often requires a collaborative approach involving healthcare professionals and the patient. This study provides valuable insights into the potential of dupilumab as a treatment option. However, it's important to discuss treatment options with a qualified healthcare professional to determine the best approach for your individual needs. Remember, a camel navigating a complex desert needs a guide to help it find its way. Similarly, managing EoE requires the expertise of healthcare professionals.

Dr.Camel's Conclusion

This study represents a significant step forward in the treatment of EoE. Just as a camel adapts to the diverse landscape of the desert, we continue to explore new ways to address the challenges of chronic diseases. Dupilumab, with its targeted approach to treating EoE, offers hope for improved treatment outcomes and a better quality of life for individuals living with this condition.

Date :
  1. Date Completed 2022-12-28
  2. Date Revised 2023-08-11
Further Info :

Pubmed ID

36546624

DOI: Digital Object Identifier

10.1056/NEJMoa2205982

Related Literature

Article Analysis
・Effective treatment of eosinophilic disorders
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.